Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34189 | 0.81 | GABRA1 (0.33) | SLC6A2ACHEMEN1KMT2A | |
| SCHEMBL29381329 | 0.81 | GABRA1 (0.33) | SLC6A2ACHEMEN1KMT2A | |
| SCHEMBL1736264 | 0.80 | HSD17B10 (0.38) | CYP2D6CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL29703806 | 0.80 | HSD17B10 (0.38) | CYP2D6CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL5928468 | 0.78 | CYP2A6 (0.34) | CYP2D6CYP1A2SLC6A2SLC6A4KCNH2 | |
| SCHEMBL9510734 | 0.77 | CYP1A2 (0.56) | CYP2D6CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL4449614 | 0.77 | RIPK1 (0.34) | CYP2D6CYP2C19LMNASLC6A2ACHE | |
| SCHEMBL30370579 | 0.75 | GABRA1 (0.34) | — | |
| SCHEMBL17750351 | 0.74 | GABRA1 (0.43) | CYP2D6SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL11586023 | 0.74 | CYP2D6 (0.53) | CYP2D6CYP1A2CYP2C19CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115315419-A | Preparation of aromatic carboxamides by palladium-catalyzed carbonylation | 巴斯夫欧洲公司 | 2022-11-08 | — | — | CN | claimed |
| CN-115298163-A | Preparation of aromatic carboxamides by palladium-catalyzed carbonylation | 巴斯夫欧洲公司 | 2022-11-04 | — | — | CN | claimed |
| EP-1565425-B1 | Production process of a lactate ester or acid | LUCITE INT UK LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| US-20060128985-A1 | Carbonylation of vinyl acetate | LUCITE INTERNATIONAL, INC. | 2006-06-15 | — | — | US | claimed |
| JP-2006508162-A | — | — | 2006-03-09 | — | — | JP | claimed |
| EP-1565425-A1 | CARBONYLATION OF VINYL ACETATE | Lucite International UK Limited (GB) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050599-A1 | CARBONYLATION OF VINYL ACETATE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
| CN-114989000-B | Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and its acylated products | 巴斯夫欧洲公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-115315419-A | Preparation of aromatic carboxamides by palladium-catalyzed carbonylation | 巴斯夫欧洲公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115298163-A | Preparation of aromatic carboxamides by palladium-catalyzed carbonylation | 巴斯夫欧洲公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114989000-A | Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and acylates thereof | 巴斯夫欧洲公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-110312701-B | Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and acylates thereof | 巴斯夫欧洲公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-111630042-A | Halogenation of pyridine derivatives | 巴斯夫欧洲公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-1816513-A | Process for the hydroformylation of olefinically unsaturated compounds | LUCITE INT UK LTD (GB) | 2006-08-09 | — | — | CN | disclosed |
| US-20060128985-A1 | Carbonylation of vinyl acetate | LUCITE INTERNATIONAL, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1651587-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1527038-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | Lucite International UK Limited (GB) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005003070-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004014834-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128985-A1 | Carbonylation of vinyl acetate | PCCA, LDHA, PC | CYP2D6 473/4885CYP1A2 296/4885CYP2C19 391/4885 |
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | CYC1, CYCS, COX5A | CYP2D6 388/4885CYP1A2 144/4885CYP2C19 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.